The Role of Hepatitis B core Antibody in improving Blood Safety in Resource- Limited Countries
Study on Voluntary blood donors Fayoum, Egypt

Corresponding author and responsible for reprint requests:
Abeer Mohamed Abdelrazik M.D
Clinical Pathology Department, Faculty of Medicine, DewanAam El Mohafza,
Fayoum, Egypt.
e.mail: abdelrazik50@hotmail.com

Hossam M. Abdelaziz M.D
Clinical Pathology Department, Faculty of Medicine, DewanAam El Mohafza,
Fayoum, Egypt.
E-mail: hma05@fayoum.edu.eg
Abstract

**Background**: Transmission of hepatitis B virus (HBV) via hepatitis B surface antigen (HBsAg) negative blood donors has been reported. HBsAg is still the only mandatory HBV screening test of blood donors in Egypt due to high cost of DNA testing of all collected blood. Many resource-limited countries have implemented screening antibodies to hepatitis B core antigen (anti-HBc) to further improve transfusion safety. The objective of study was to evaluate the significance of screening anti-HBc to reduce the risk of transfusion transmitted HBV infection in Egypt.

**Study design and methods**: study was conducted on 800 voluntary blood donors negative for HBsAg, hepatitis C antibody (HCVAb) and human immunodeficiency virus Ab. They were subjected to screening for anti-HBV core antibodies (total). Anti-HBc-positive samples were further tested for the antibodies to HBsAg (anti-HBs), and "anti-HBc alone" sera were tested for HBV DNA. Among 800 healthy voluntary donors, 99 (12.37%) were anti-HBc-positive including 78 anti-HBs positive. The remaining 21 donors were anti-HBc alone, 2 of which (9.52%) were HBV DNA-positive.

**Conclusion**: Greater consideration should be given to the implementation of anti-HBc as an additional screening test for blood donors in Egypt as the most cost-effective measure for further improvement of transfusion safety.

**Key words**: anti-HBc; anti-HBc alone; blood donors; occult HBV infection.
Introduction:

In Egypt, current mortality due to liver disease, including liver cirrhosis and cancer, is over 40,000/year and is increasing annually. It is estimated that approximately 400 million people worldwide are chronically infected with HBV, where Egypt is considered as an area of intermediate endemicity (29). Hepatitis B virus (HBV) is easily transmitted by blood products as both cellular and plasma-derived components may be infected (6). Transfusion-transmitted HBV played a major role in the spread of this infection some decades ago all around the world, and is still a threat in developing countries, where the prevalence of this infection is higher and the donor selection and screening procedures are less tight (6, 18).

Occult hepatitis B infection (OBI) is defined by the presence of HBV DNA in the liver tissue of individuals who test negative for HBsAg, regardless of the detection of HBV DNA in serum (23). OBI was reported for the first time almost 30 years ago in a case report of HBV infection through blood transfusion by an antibody to hepatitis B core antigen (anti-HBc) only positive donor (33).

In most developed countries, nucleic acid amplification testing (NAT) has been introduced along with serological testing for HBV, hepatitis C virus and human immunodeficiency virus in order to enhance blood safety (8, 24, 1). In contrast, developing countries with limited resources cannot implement NAT for screening of all donor collected blood and are relying on proper donor selection which is complemented by sensitive cost-effective serological screening tests to exclude the transmission of infective agents (19, 21).
In Egypt, screening for HBsAg is the only mandatory screening test for the detection of Hepatitis B virus (HBV) infection in blood banks\(^{29}\). Only four qualified blood centres are already implementing NAT in Egypt, and these are National Cancer Institute (NCI) blood bank, blood bank of Nasser Institute, blood bank of EL-Shabrowishy Hospital (Private hospital) and the Egyptian Organization for Biological Products and Vaccines (VACCERA) blood bank\(^{27}\). Given the constrained economy, lack of appropriate infrastructure and inadequate trained personnel limit its implementation in all blood banks\(^{25,10}\). New cost-effective strategies and stringent donor selection implementation are very important measures to ensure blood safety in resource-limited countries.

Unlike HCV, HBV cannot be cured, and the treatment for it is life-long. National Committee for the Control of Viral Hepatitis in Egypt estimated the cost of HBV treatment ranges from 250-550 Egyptian L.E/ patient monthly according to the anti-viral treatment used. In addition to the expenses of advanced liver disease care\(^9\), it is clear that treatment costs are not comparable to the cost-effective preventive measures that have to be implemented.

The aim of this study was to determine the presence of HBcAb and HBV DNA among HBsAg negative healthy blood donors in Fayoum University Hospital Blood Bank to evaluate the significance of implementing screening anti-HBe to reduce the risk of transfusion transmitted HBV infection in Egyptian blood banks.
Materials and Methods:

Blood samples

The present study included 800 samples from blood donors negative for anti-hepatitis C antibody (HCV), anti-human immunodeficiency virus (HIV), and HBsAg collected over a period of 6 months (from April 2014 to September 2014) in Fayoum university hospital blood bank.

Detection of Serologic Markers

Serum HBV total anti-HBc was performed by ELISA technique, Monoliza Anti-hepatitis B core Plus-Bio-Rad, according to manufacturer’s instructions on all donor samples. Positive samples were subjected to quantitative detection of antibodies to hepatitis B surface (anti-HBs) with commercially available kits (ETI-AB-AUK-3, DiaSorin-Italy). Serum anti-HBs titers > 10 IU/L was considered positive.

Detection of Hepatitis B Viral DNA

HBV DNA level was estimated for blood units with low or undetectable serum anti-HBs levels "anti-HBc alone" using real time polymerase chain reaction (PCR) automated system. HBV fluorescence quantitative diagnostic kit (Hangzhou Bioer Technology, China). The kit combines the Viral DNA extraction and the technologies of nucleic acid amplification and hybridization probe. Real-time PCR was performed on the Chromo4 DNAEnginePeltier thermal Cycler (BIO-RAD, Hercules, CA). Thermal profile was set according to manufacturer’s guideline.
**Statistical analysis**

Data were statistically described in terms of frequencies (number of cases) and percentages when appropriate. All statistical calculations were done using computer programs Microsoft Excel 2003 (Microsoft Corporation, NY, and USA) and SPSS (Statistical Package for the Social Science; SPSS Inc., Chicago, IL, USA) version 15 for Microsoft Windows.

**Results:**

**Serological results**

All participants were negative for HBsAg. 99/800 (12.37 %) of blood donors were negative for HBsAg and positive for anti-HBc. Anti-HBs antibody was detected in 78/99 (78.78%) of HBsAg negative and anti-HBc positive samples, with serum levels > 10 IU/L.

**Molecular findings**

Detection of HBV-DNA was performed on all samples that were negative for HBsAg and positive for anti-HBc antibody only by use of real time PCR technique. HBV-DNA was detected in 2 out of 21 anti-HBc positive specimens (9.52%).

**Discussion:**

OBI is defined as the presence of HBV DNA in the liver (with detectable or undetectable HBV DNA in the serum) of individuals who tested negative for HBsAg\(^{(26)}\). Occult HBV is transmissible by blood transfusion, although the transmission rate is considered to be very low. The clinical outcome of OBI transmission mainly depends on the immune status and copies of HBV DNA in blood products of the recipient\(^{(30)}\). At present, HBsAg detection is the only
obligatory diagnostic screening test for HBV infection in blood transfusion centers in Egypt. We examined 800 HBsAg negative sera obtained from healthy blood donors and found that 12.37% of them were positive for anti-HBc, which is comparable to two previous Egyptian studies with a prevalence of 14.2% and 10.9% of HBsAg negative volunteer blood donors. The study is also comparable to the older anti-HBc prevalence rates reported among HBsAg-negative blood donors in India; 10.01% and 11.2% in Syria, respectively.

The prevalence of anti-HBc only in Europe and North America is overall quite low. A prevalence of 0.07% in the UK and 1.5% in Germany was reported. In areas of higher HBV infection prevalence about 20%-70% of subjects are positive for anti-HBc antibody. In our study the overall prevalence of occult HBV infection in healthy blood donors was 9.52% among anti-HBc positive alone individuals. Different results have been reported in other studies regarding the rate of OBI in blood donors. These differences in the occult HBV prevalence may be attributed to race and ethnicity, geographical area and the HBV subtypes. The frequency of HBV-DNA detected in HBsAg negative samples also varies considerably according to the prevalence of the infection. In Northern countries where the prevalence of chronic infection is less than 1%, no more than 5% of HBsAg negative /anti-HBc positive blood donor samples contain HBV-DNA. In contrast, higher OBI levels in HBsAg-negative blood were recorded in several published reports. In India, the prevalence was 24% and in a published study from Korea, 16% of the studied sample was found to be positive for OBI. Other reports of the prevalence of HBV-DNA in only anti-HBc positive blood donors revealed 0% in Brazil, 0.3% in China, 1.1% in Japan, 3.2% in Saudi Arabia and 12.7% in Ghana. Some information is available regarding the infectivity of anti-HBc-only blood products or organs. The infectivity of blood donations containing anti-HBc as the only marker of HBV
infection has been known for several decades and indicated that no more than 4% of recipients of anti-HBc-only blood developed HBV infection post-transfusion\(^{(17)}\) However, Mosley reported 17% infectivity of antiHBc-only blood products\(^{(14,20)}\). Anti-HBc screening has the potential of excluding the vast majority of occult HBV infection but this exclusion of anti-HBc positive donors is impractical in countries where HBV infection is prevalent and higher than 20% of the populations are anti-HBc positive\(^{(12)}\). The use of HBV anti core testing to eliminate the residual transfusion risk of transmission of HBV has not been evaluated in Egypt.

**Conclusion:**

One of the main mechanisms for OBI transmission is most likely through infected blood and its components and our findings revealed that OBI exists among Egyptian blood donors. Screening for HBsAg in blood banks in Egypt is not sufficient to completely exclude HBV infection in an intermediately endemic area like Egypt. NAT cannot be implemented for screening of all donor collected blood because of the high cost for a resource-limited country like Egypt. New screening policy to further increase the safety of blood transfusion is strongly indicated.

Anti-HBc antibody should be tested routinely on blood donor volunteers, and if the sera become positive regardless of anti-HBs titer, the blood should be discarded. Further testing for HBV-DNA is appropriate to follow up the blood donor patient for HBV infection.

**References**

1. Allain JP, Candotti D. Diagnostic algorithm for HBV safe transfusion. Blood Transf 2009; 7: 174-82.

2. Allain JP, Hewitt PE, Tedder RS, Williamson LM. Evidence that anti-HBe but not HBV
DNA testing may prevent some HBV transmission by transfusion. Br J Haematol. 1999 Oct; 107(1): 186-195.

(3) Allain JP. Occult hepatitis B virus infection: implications in transfusion. Vox Sang 2004; 86: 83-91.

(4) Almeida-Neto C, Strauss E, Sabino EC, Sucupira MC, Chamone DA. Significance of isolated hepatitis B core antibody in blood donors from Sao Paulo. Rev Inst Med Trop Sao Paulo. 2001 Jul-Aug; 43(4):203-208.

(5) Bernvil SS, Andrews V, Kuhns MC, McNamara AL. Hepatitis B core antigen antibody as an indicator of a low grade carrier state for hepatitis B virus in a Saudi Arabian blood donor population. Transfus Sci. 1997 Mar; 18(1):49-53.

(6) Candotti D, Allain JP. Transfusion-transmitted hepatitis B virus infection. J Hepatol 2009; 51: 798-809.

(7) Comanor L, Holland P. Hepatitis B virus blood screening: unfinished agendas. Vox Sang 2006 Jul; 91(1):1-12.

(8) De Mitri MS, Cassini R, Bernardi M. Hepatitis B virus-related hepatocarcinogenesis: molecular oncogenic potential of clear or occult infections. Eur J Cancer. 2010; 46:2178–2186.

(9) Egyptian national control strategy for viral hepatitis, National Committee for the Control of Viral Hepatitis 2008-2012.

(10) El-Zayadi AR1, Ibrahim EH, Badran HM, et al. Anti-HBc screening in Egyptian blood donors reduces the risk of hepatitis B virus transmission. Transfus Med. 2008 Feb; 18(1):55-61.

(11) Gerlich WH, Wagner FF, Chudy M, et al. HBsAg non-reactive HBV infection in blood donors: transmission and pathogenicity. J Med Virol 2007; 79: S32-36.

(12) Grob P, Jilg W, Bornhak H, Gerlich W. Serological pattern "anti-HBc alone": report on a workshop. J Med Virol. 2000 Dec; 62(4): 450-455
(13) Hennig H, Puchta I, Luhm, et al. Frequency and load of hepatitis B virus DNA in first-time blood donors with antibodies to hepatitis B core Antigen. Blood. 2002 Oct 1; 100(7): 2637-2641.

(14) Jafarzadeh, M. KazemiArababadi , M. Mirzaee and A. Pourazar. Occult hepatitis B virus infection among blood donors with antibodies to hepatitis B core antigen. ActaMedicalIranica 2008. 46(1):27-32.

(15) Kim SM, Lee KS, Park CJ, Lee JY, Kim KH, Park JY, et al. Prevalence of occult HBV infection among subjects with normal serum ALT levels in Korea. J Infect. 2007; 54:185–191.

(16) Kleinman SH, Kuhns MC, Todd DS, Glynn SA, McNamara A. Frequency of HBV DNA detection in US blood donors testing positive for anti-HBc: implications for transfusion transmission and donor screening. Transfusion 2003 Jun; 43(6): 696-704.

(17) Kwok S, Higushi R. Avoiding false positives with PCR. Nature 1989 May 18; 339(6221): 237-8.

(18) Luisa Romanò, Claudio Velati, Giuseppe Cambièet al. Hepatitis B virus infection among first-time blood donors in Italy: Prevalence and correlates between serological patterns and occult infection. Blood Transfus 2013; 11: 281-8.

(19) Maheswari K S, Arun R, ArumugamP. Prevalence of the Hepatitis B Core Antibody and the Occult Hepatitis B Infection among Voluntary Blood Donors in Chennai, India. Journal of Clinical and Diagnostic Research. 2012 December, Vol-6(10): 1710-1712.

(20) Mosley JW, Stevens CE, Aach RD, Hollinger FB, Mimms LT, Solomon LR, Barbosa LH, Nemo GJ. Donor screening for antibody to hepatitis B core antigen and hepatitis B virus infection in transfusion recipients. Transfusion 1995 Jan; 35(1):5-12.

(21) Muselmani W, Habbal W, Monem F. Signifidcance of screeingantibodies to hepatitis B virus core antigen among Syrian. Transfus Med. 2013 Aug; 23(4):265-8.

(22) Nandi J, Benerjee K. Detection of hepatitis B virus DNA in donor blood by
polymerase chain reaction. Nal Med J India. 1992;5:5-7.

(23) Nishikawa H1, Osaki Y. Clinical Significance of Occult Hepatitis B Infection in Progression of Liver Disease and Carcinogenesis. J Cancer. 2013 Jul 11; 4(6):473-80.

(24) Nubling CM, Heiden M, Chudy M, et al. Experience of mandatory nucleic acid test (NAT) screening across all blood organizations in Germany: NAT yield versus breakthrough transmissions. Transfusion 2009; 49: 1850-8.

(25) Omran D, Hussein EA, Nagib M. Safety of Blood Transfusion: An Egyptian Study. J Infect Dis Ther. 2013, 1: 124.

(26) Raimondo G, Allain JP, Brunetto MR, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008; 49: 652-657.

(27) Rekha Hans and Neelam Marwaha. Nucleic acid testing benefits and constraints. Asian J Transfus Sci. 2014 Jan-Jun; 8(1): 2-3.

(28) Ren F, Li H, Zhao H. Studies on hepatitis B virus infection in blood donors with positive anti-HBc and negative HBsAg. Zhonghua Yu Fang Yi Xue ZaZhi. 1998 Jan; 32(1):7-9.

(29) Said ZN1, Sayed MH, Salama II, et al. Occult hepatitis B virus infection among Egyptian blood donors. World J Hepatol. 2013 Feb 27;5(2):64-73

(30) Satake M, Taira R, Yugi H, Hino S, et al. Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program. Transfusion 2007; 47: 1197-1205.

(31) Sato S, Ohashi W, Ihara H, Sakaya S, Kato T, Ikeda H. Comparison of the sensitivity of NAT using pooled donor samples for HBV and that of a serologic HBsAg assay. Transfusion. 2001 Sep; 41(9): 1107-1113.

(32) Zahn A, Li C, Danso K, Candotti D, Owusu-Ofori S, Temple J, Allain JP. Molecular characterization of occult hepatitis B virus in genotype E-infected subjects. J Gen Virol. 2008 Feb; 89(Pt 2):409-418.

(33) Zeinab Nabil Ahmed Said. An overview of occult hepatitis B virus infection. World J
الملخص العربي
دور المستضد الأساسي لفيروس الإلتهاب الكبدي "بي" في زيادة الأمان في بنوك الدم بالدول المحدودة الدخول
دراسة عن المتبرعين المتطوعين بالدم الفيوم- مصر

في الوقت الحاضر يعتبر الأنتيجين السطحي لفيروس بي هو الفحص الوحيد الإلزامي لتشخيص الأنتي فير إكز نقل الدم في مصر. أجريت الدراسة على 800 من المتبرعين المتطوعين ونتائجهم سلبية لكل من الأنتيجين السطحي لفيروس بي وأضداد فيروس الإلتهاب الكبدي سي وأجسام المسادة لفيروس نقص المناعة من بين ال 800 متبرع وجد أن 99 (12.3%) منهم المستضد الأساسي لفيروس الإلتهاب الكبدي "بي". و21 متبرع حمد كان نتائجه إيجابية للمستضد السطحي لفيروس "بي" و22 متبرع حمد كان نتائجه إيجابية للمستضد الأساسي لفيروس "بي" فقط ومنهم حالتين فقط (2.52%) كانت نتائج تحليل الحمض النووي دي ان أي إيجابي. سللت هذه الدراسة الضوء على مدى أهمية فحص تلك الأجسام المضادة كوسيلة أقل تكلفة للحد من مخاطر الأصابة بهذا الفيروس من نقل الدم.